Actions of delta-9-tetrahydrocannabinol in cannabis: Relation to use, abuse, dependence

International Review of Psychiatry

Volumn 21, Issue 2 SPEC. ISS., 2009, Pages 104-112

  Cooper, Ziva D ^b   Haney, Margaret ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABIS; DEXANABINOL; DRONABINOL; NALOXONE; RIMONABANT;

CANNABIS ADDICTION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; WITHDRAWAL SYNDROME;

ANIMALS; CANNABIS; HUMANS; MARIJUANA ABUSE; MARIJUANA SMOKING; RECEPTOR, CANNABINOID, CB1; REINFORCEMENT (PSYCHOLOGY); TETRAHYDROCANNABINOL;

EID: 67651031552     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.1080/09540260902782752     Document Type: Review

References (103)

1. Ator, N.A., & Griffiths, R.R. (2003). Principles of drug abuse liability assessment in laboratory animals. Drug & Alcohol Dependence, 70(Suppl.3), S55-72.
2. Bardo, M.T., & Bevins, R.A. (2000). Conditioned place preference: What does it add to our preclinical understanding of drug reward? Psychopharmacology, 153, 31-43.
3. Bauman, A., & Phongsavan, P. (1999). Epidemiology of substance use in adolescence: Prevalence, trends, and policy implications. Drug & Alcohol Dependence, 55, 187-207. (Pubitemid 29248943)
4. Benowitz, N.L., & Jones, R.T. (1981). Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. Journal of Clinical Pharmacology, 21, 214S-223S.
5. Bortolato, M., Campolongo, P., Mangieri, R.A., Scattoni, M.L., Frau, R., Trezza, V. et al. (2006). Anxioloytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology, 31, 2652-2659. (Pubitemid 44764162)
6. Braida, D., Pozzi, M., Cavallini, R., & Sala, M. (2001). Conditioned place preference induced by the cannabinoid agonist CP 55,940: Interaction with the opioid system. Neuroscience, 104, 923-926.
7. Braida, D., Iosue, S., Pegorini, S., & Sala, M. (2004). Delta9-tetrahydrocannabinol-induced conditioned place preference and introcerebroventricular self-administration in rats. European Journal of Pharmacology, 506, 63-69. (Pubitemid 39575086)
8. Budney, A.J., Novy, P.L., & Hughes, J.R. (1999). Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction, 94, 1311-1321.
9. Budney, A.J., Hughes, J.R., Moore, B.A., & Vandrey, R. (2004). Review of the validity and significance of cannabis withdrawal syndrome. American Journal of Psychiatry, 161, 1967-1977
10. Budney, A.J., Hughes, J.R., Moore, B.A., & Novy, P.L. (2001). Marijuana abstinence effects in marijuana smokers maintained in their home environment. Arch Gen Psychiatry, 58, 917-924.
11. Budney, A.J., Vandrey, R.G., Hughes, J.R., Moore, B.A., & Bahrenburg, B. (2007). Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug & Alcohol Dependence, 86, 22-29. (Pubitemid 44708528)
12. Carney, J.M., Uwaydah, I.M., & Balster, R.L. (1977). Evaluation of a suspension system for intravenous self-administration of water insoluble substances in the rhesus monkey. Pharmacology Biochemistry and Behaviour, 7, 357-364. (Pubitemid 8238456)
13. Castañé, A., Robledo, P., Matifas, A., Kieffer, B.L., & Maldonado, R. (2003). Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice. European Journal of Neuroscience, 17, 155-159. (Pubitemid 36098886)
14. Chait, L.D., & Zacny, J.P. (1992). Reinforcing and subjective effects of oral delta 9-THC and smoked marijuana in humans. Psychopharmacology, 107, 255-262.
15. Chaperon, F., Soubrie, P., Puech, J., & Thiebot, M.H. (1998). Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology, 135, 324-332. (Pubitemid 28254837)
16. Cheer, J.F., Kendall, D.A., & Marsden, C.A. (2000). Cannabinoid receptors and reward in the rat: A conditioned place preference study. Psychopharmacology, 151, 25-30. (Pubitemid 30639836)
17. Compton, W.M., Grant, B.F., Colliver, J.D., Glantz, M.D., & Stinson, F.S. (2004). Prevalence of marijuana use disorders in the United States: 1991-1992 and 2001-2002. Journal of the American Medical Association, 291, 2114-2121. (Pubitemid 38580155)
18. Cooper, Z.D., & Haney, M. (in press). Comparison of subjective, pharmacokinetic, and physiologic effects of cannabis smoked as joints and blunts. Drug & Alcohol Dependence.
19. Deiana, S., Fattore, L., Spano, M.S., Cossu, G., Porcu, E., Fadda, P. et al. (2007). Strain and schedule-dependent differences in the acquisition, maintenance and extinction of intravenous cannabinoid self-administration in rats. Neuropsychopharmacology, 52, 646-654. (Pubitemid 46151687)
20. Fadda, P., Scherma, M., Spano, M.S., Salis, P., Melis, V., Fattore, L. et al. (2006). Cannabinoid self-administration increases dopamine release in the nucleus accumbens. Neuroreport, 17, 1629-1632. (Pubitemid 44454770)
21. Fattore, L., Cossu, G., Martellotta, C.M., & Fratta, W. (2001). Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Psychopharmacology, 156, 410-416. (Pubitemid 32695850)
22. Fattore, L., Spano, M.S., Altea, S., Angius, F., Fadda, P., & Fratta, W. (2007). Cannabinoid self-administration in rats: Sex differences and the influence of ovarian function. British Journal of Pharmacology, 152, 795-804. (Pubitemid 350034986)
23. Felder, C.C., & Glass, M. (1998). Cannabinoid receptors and their endogenous agonists. Annual Review of Pharmacology and Toxicology, 38, 179-200. (Pubitemid 28231493)
24. Fredericks, A.B., & Benowitz, N.L. (1980). An abstinence syndrome following chronic administration of delta-9-tetrahydrocannabinol in rhesus monkeys. Psychopharmacology, 71, 201-202. (Pubitemid 11254059)
25. Gardner, E.L., & Vorel, S.R. (1998). Cannabinoid transmission and reward-related events. Neurobiology of Disease, 5(6 Pt B), 502-533.
26. Georgotas, A., & Zeidenberg, P. (1979). Observations on the effects of four weeks of heavy marijuana smoking on group interaction and individual behavior. Comprehensive Psychiatry, 20, 427-432. (Pubitemid 10243004)
27. Haney, M. (2002). Effects of smoked marijuana in healthy and HIV+ cannabis smokers. Journal of Clinical Pharmacology, 42, 34S-40S.
28. Haney, M. (2005). The marijuana withdrawal syndrome: Diagnosis and treatment. Current Psychiatry Reports, 7, 360-366. (Pubitemid 41684183)
29. Haney, M. (2007). Opioid antagonism of cannabinoid effects: Differences between marijuana smokers and nonmarijuana smokers. Neuropsychopharmacology, 32, 1391-1403.
30. Haney, M. (2008). Self-administration of cocaine, cannabis and heroin in the human laboratory: Benefits and pitfalls. Addiction Biology, 14, 9-21.
31. Haney, M., Bisaga, A., & Foltin, R.W. (2003). Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology, 166, 77-85. (Pubitemid 36286723)
32. Haney, M., Comer, S.D., Ward, A.S., Foltin, R.W., & Fischman, M.W. (1997). Factors influencing marijuana self-administration by humans. Behavioral Pharmacology, 8, 101-112. (Pubitemid 27303906)
33. Haney, M., Hart, C.L., Vosburg, S.K., Nasser, J., Bennett, A., Zubaran, C. et al. (2004). Marijuana withdrawal in humans: Effects of oral THC or divalproex. Neuropsychopharmacology, 29, 158-170. (Pubitemid 38068026)
34. Haney, M., Hart, C.L., Ward, A.S., & Foltin, R.W. (2003). Nefazodone decreases anxiety during marijuana withdrawal in humans. Psychopharmacology, 165, 157-165. (Pubitemid 36056992)
35. Haney, M., Ward, A.S., Comer, S.D., Foltin, R.W., & Fischman, M.W. (1999a). Abstinence symptoms following oral THC administration to humans. Psychopharmacology, 141, 385-394. (Pubitemid 29190007)
36. Haney, M., Ward, A.S., Comer, S.D., Foltin, R.W., & Fischman, M.W. (1999b). Abstinence symptoms following smoked marijuana in humans. Psychopharmacology, 141, 395-404. (Pubitemid 29190008)
37. Harris, R.T., Waters, W., & McLendon, D. (1974). Evaluation of reinforcing capability of Δ9-tetrahydrocannabinol in monkeys. Psychopharmacologia, 37, 23-29.
38. Hart, C.L., Haney, M., Vosburg, S.K., Comer, S.D., & Foltin, R.W. (2005). Reinforcing effects of oral Δ9-THC in male marijuana smokers in a laboratory choice procedure. Psychopharmacology, 181, 237-243. (Pubitemid 41492193)
39. Hart, C.L., Haney, M., Ward, A.S., Fischman, M.W., & Foltin, R.W. (2002a). Effects of oral THC maintenance on smoked marijuana self-administration. Drug & Alcohol Dependence, 67, 301-309. (Pubitemid 34786265)
40. Hart, C.L., van Gorp, W.G., Haney, M., Foltin, R.W., & Fischman, M.W. (2001). Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology, 29, 158-170.
41. 9-tetrahydrocannabinol in humans. Psychopharmacology, 164, 407-415.
42. Hirschhorn, I.D., & Rosecrans, J.A. (1974). Morphine and delta 9-tetrahydrocannabinol: Tolerance to the stimulus effects. Psychopharmacologia, 36, 243-253.
43. Huestis, M.A., Boyd, S.J., Heischman, S.J., Preston, K.L., Bonnet, D., Le Fur, G. et al. (2007). Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology, 194, 505-515 (Pubitemid 47492992)
44. Huestis, M.A., Gorelick, D.A., Heishman, S.J., Preston, K.L., Nelson, R.A., Moolchan, E.T. et al. (2001). Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Archives of General Psychiatry, 58, 322-328.
45. Hutcheson, D.M., Tzavara, E.T., Smadja, C., Valjent, E., Roques, B.P., Hanoune, J. et al. (1998). Behavioral and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. British Journal of Pharmacology, 125, 1567-1577. (Pubitemid 28548570)
46. Jarbe, T.U., Lamb, R.J., Lin, S., & Makriyannis, A. (2001). (R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: Tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacology, 156, 369-380. (Pubitemid 32695845)
47. Jarbe, T.U., Liu, Q., & Makriyannis, A. (2006). Antagonism of discriminative stimulus effects of Δ9-THC and (R)-methanandamide in rats. Psychopharmacology, 184, 36-45. (Pubitemid 43005755)
48. Jones, R.T., Benowitz, N., & Bachman, J. (1976). Clinical studies of cannabis tolerance and dependence. Annals of the New York Academy of Science, 282, 221-239. (Pubitemid 8023834)
49. Jones, R.T., Benowitz, N., & Herning, R.I. (1981). Clinical relevance of cannabis tolerance and dependence. Journal of Clinical Pharmacology, 21, 143S-152S.
50. Justinova, Z., Tanda, G., Munzar, P., & Goldberg, S.R. (2004). The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. Psycopharmacology, 173, 186-194. (Pubitemid 38591164)
51. Justinova, Z., Tanda, G., Redhi, G.H., & Goldberg, S.R. (2003). Self-administration of Δ9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology, 169, 135-140. (Pubitemid 37129964)
52. Justinova, Z., Munzar, P., Panlilio, L.V., Yasar, S., Redhi, G.H., Tanda, G. et al. (2008). Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant. Neuropsychopharmacology, 33, 2870-2877.
53. Kaymakcalan, S. (1973). Tolerance to and dependence on cannabis. Bulletin on Narcotics, 25, 39-47.
54. Kaymakcalan, S., Ayhan, I.H., & Tulunay, F.C. (1977). Naloxone-induced or postwithdrawal abstinence signs in delta9- tetrahydrocannabinol-tolerant rats. Psychopharmacology, 55, 243-249. (Pubitemid 8243201)
55. Kelly, T.H., Foltin, R.W., Emurian, C.S., & Fischman, M.W. (1997). Are choice and self-administration of marijuana related to delta 9-THC content? Experimental and Clinical Psychopharmacology, 5, 74-82.
56. Kouri, E.M., & Pope Jr, H.G. (2000). Abstinence symptoms during withdrawal from chronic cannabis use. Exp Clinical Psychopharmacology, 8, 483-492.
57. Landsman, R.S., Burkey, T.H., Consroe, P., Roeske, W.R., & Yamamura, H.I. (1997). SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. European Journal of Pharmacology, 334, R1-R2. (Pubitemid 27417820)
58. Leite, J.R., & Carlini, E.A. (1974). Failure to obtain "cannabis-directed behavior" and abstinence in rats chronically treated with cannabis sativa extracts. Psychopharmacologia, 8, 133-145.
59. Lepore, M., Vorel, S.R., Lowinson, J., & Gardner, E.L. (1995). Conditioned place preference induced by Δ9-tetrahydrocannabinol: Comparison with cocaine, morphine, and food reward. Life Science, 56, 2073-2080.
60. Lichtman, A.H., Sheikh, S.M., Loh, H.H., & Martin, B.R. (2001). Opioid and cannabinoid modulation of precipitated withdrawal in Δ9-tetrahydrocannabinol and morphine-dependent mice. Journal of Pharmacology and Experimental Therapeutics, 298, 1007-1014. (Pubitemid 32761916)
61. Lichtman, A.H., & Martin, B.R. (2005). Cannabinoid tolerance and dependence. Handbook of Experimental Pharmacology, 168, 691-717.
62. Lile, J.A., Kelly, T.H., Hudson D.A., & Hays, L.R. (2008). Substitution profile of THC, nabilone, triazolam, hydromorphone, and methylphenidate in humans discriminating THC. 18th Annual International Cannaboinoid Research Society, Aviemore, Scotland.
63. Mansbach, R.S., Nicholson, K.L., Martin, B.R., & Balster, R.L. (1994). Failure of Δ9-tetrahydrocannabinol and CP 55,940 to maintain intravenous self-administration under a fixed-interval schedule in rhesus monkeys. Behavioral Pharmacology, 5, 219-225. (Pubitemid 24153745)
64. Mansbach, R.S., Rovetti, C.C., Winston, E.N., & Lowe III, J.A. (1996). Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats. Psychopharmacology, 124, 315-322.
65. Martellotta, M.C., Cossu, G., Fattore, L., Gessa, G.L., & Fratta, W. (1998). Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. Neuroscience, 85, 327-330. (Pubitemid 28218655)
66. McGregor, I.S., Issakidis, C.N., & Prior, G. (1996). Aversive effects of the synthetic cannabinoid CP 55,940 in rats. Pharmacology Biochemistry, and Behaviour, 53, 657-664.
67. McMahon, L.R., & France, C.P. (2003). Discriminative stimulus effects of the cannabinoid antagonist, SR 141716A, in Δ9-tetrahydrocannabinol- treated rhesus monkeys. Experimental Clinical Psychopharmacology, 11, 286-293. (Pubitemid 37433441)
68. McMahon, L.R. (2006). Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9- tetrahydrocannabinol. Psychopharmacology, 188, 306-314.
69. Mendelson, J.H., & Mello, N.K. (1984). Reinforcing properties of oral Δ9-tetrahydrocannabinol, smoked marijuana, and nabilone: Influence of previous cannabis use. Psychopharmacology, 83, 351-356.
70. Mendelson, J.H., Mello, N.K., Lex, B.W., & Bavli, S. (1984). Marijuana withdrawal syndrome in a woman. American Journal of Psychiatry, 141, 1289-1290.
71. Navarro, M., Chowen, J., Rocío, A., Carrera, M., del Arco, I., Villanúa, M.A. et al. (1998). CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats. Neuroreport, 9, 3397-3402 (Pubitemid 28566119)
72. Navarro, M., Carrera, M.R., Fratta, W., Valverde, O., Cossu, G., Fattore, L. et al. (2001). Functional interaction between opioid and cannabinoid receptors in drug self-administration. Journal of Neuroscience, 21, 5344-5350. (Pubitemid 32622960)
73. Nowlan, R., & Cohen, S. (1977). Tolerance to marijuana: Heart rate and subjective 'high'. Clinical Pharmacol Therapy, 22, 550-556.
74. Parker, L.A., & Gillies, T. (1995). THC-induced place and taste aversions in Lewis and Sprague-Dawley rats. Behavioral Newuroscience, 109, 71-78.
75. Pickens, R., Thompson, T., & Muchow, D.C. (1973). Cannabis and phencyclidine self-administered by animals. In L. Goldfarb & F. Hoffmeister (Eds.), Psychic dependence (Bayer-Symposium IV) (pp. 78-86). Heidelberg, New York, Springer: Berlin.
76. Reilly, D., Didcott, P., Swift, W., & Hall, W. (1998). Long-term cannabis use: Characteristics of users in an Australian rural area. Addiction, 93, 837-846. (Pubitemid 28287071)
77. Robledo, P., Berrendero, F., Ozaita, A., & Maldonado, R. (2008). Advances in the field of cannabinoid-opioid cross-talk. Addiction, 13, 213-224.
78. Solinas, M., & Goldberg, S.R. (2005). Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems. Neurospychopharmacology, 30, 2035-2045. (Pubitemid 43093503)
79. Solinas, M., Panlilio, L.V., Justinova, Z., Yasar, S., & Goldberg, S.R. (2006). Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats. Nature Protocols, 1, 1194-1206.
80. Solinas, M., Tanda, G., Justinova, Z., Wertheim, C.E., Yasar, S., Piomelli, D. et al. (2007). The endogenous cannabinoid anandamide produces δ-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. Journal of Pharmacology and Experimental Therapeutics, 321, 370-380. (Pubitemid 46456957)
81. Spano, M.S., Fattore, L., Cossu, G., Deiana, S., Fadda, P., & Fratta, W. (2004). CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat. British Journal of Pharmacology, 143, 343-350. (Pubitemid 39424822)
82. Stephens, R.S., Roffman, R.A., & Curtin, L. (2000). Comparison of extended versus brief treatments for marijuana use. Journal of Consulting and Clinical Psychology, 68, 898-908.
83. Tanda, G., & Goldberg, S.R. (2003). Cannabinoids: Reward, dependence, and underlying neurochemical mechanisms - A review of recent preclinical data. Psychopharmacology, 169, 115-134. (Pubitemid 37129963)
84. Tanda, G., Loddo, P., & Di Chiara, G. (1999). Dependence of mesolimbic dopamine transmission on delta 9-tetrahydrocannabinol. European Journal of Pharmacology, 376, 23-26. (Pubitemid 29320166)
85. Tanda, G., Munzar, P., & Goldberg, S.R. (2000). Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nature Neuroscience, 3, 1073-1074. (Pubitemid 30828175)
86. Tanda, G., Pontieri, F.E., & Di Chiara, G. (1997). Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common μ1 opioid receptor mechanism. Science, 276, 2048-2050. (Pubitemid 27443611)
87. Tulunay, F.C., Ayhan, I.H., Portoghese, P.S., & Takemori, A.E. (1981). Antagonism by chlornaltrexamine of some effects of delta 9-tetrahydrocannabinol in rats. European Journal of Pharmacology, 70, 219-224.
88. Valjent, E., & Maldonado, R. (2000). A behavioural model to reveal place preference to Δ9-tetrahydrocannabinol in mice. Psychopharmacology, 147, 436-438. (Pubitemid 30048492)
89. Valverde, O., Maldonado, R., Valjent, E., Zimmer, A.M., & Zimmer, A. (2000). Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice. Journal of Neuroscience, 20, 9284-9289. (Pubitemid 32042932)
90. Vandrey, R., Budney, A.J., Kamon, J.L., & Stanger, C. (2005). Cannabis withdrawal in adolescent treatment seekers. Drug & Alcohol Dependence, 78, 205-210. (Pubitemid 40544608)
91. Vlachou, S., Nomikos, G.G., & Panagis, G. (2005). CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat. Psychopharmacology, 179, 498-508. (Pubitemid 40569051)
92. Wachtel, S.R., & de Wit, H. (2000). Naltrexone does not block the subjective effects of oral delta (9)-tetrahydrocannabinol in humans. Drug & Alcohol Dependence, 59, 251-260.
93. Wachtel, S.R., ElSohly, M.A., Ross, S.A., Ambre, J., & de Wit, H. (2002). Comparison of the subjective effects of δ9-tetrahydrocannabinol and marijuana in humans. Psychopharmacology, 161, 331-339. (Pubitemid 34595783)
94. Ward, A.S., Comer, S.D., Haney, M., Foltin, R.W., & Fischman, M.W. (1997). The effects of a monetary alternative on marijuana self-administration. Behav Pharmacol, 8, 275-286. (Pubitemid 27402095)
95. Wiesbeck, G.A., Schuckit, M.A., Kalmijn, J.A., Tipp, J.E., Bucholz, K.K., & Smith, T.L. (1996). An evaluation of the history of a marijuana withdrawal syndrome in a large population. Addiction, 91, 1469-1478.
96. Wiley, J.L., LaVecchia, K.L., Karp, N.E., Kulasegram, S., Mahadevan, A., Razdan, R.K. et al. (2004). A comparison of the discriminative stimulus effects of delta(9)-tetrahydrocannabinol and O-1812, a potent and metabolically stable anandamide analog, in rats. Exp Clinical Psychopharmacology, 12, 173-179.
97. Wiley, J.L., Lowe, J.A., Balster, R.L., & Martin, B.R. (1995). Antagonism of the discriminative stimulus effects of Δ9- tetrahydrocannabinol in rats and rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics, 75, 1-6.
98. Wilson, D.M., Varvel, S.A., Harloe, J.P., Martin, B.R., & Lichtman, A.H. (2006). SR 141716 (Rimonabant) precipitates withdrawal in cannabis-dependent mice. Pharmacology Biochemistry Behavior, 85, 105-113.
99. Wise, R.A. (1996). Addictive drugs and brain stimulation reward. Annual Review of Neuroscience, 19, 319-340.
100. Young, S.E., Corley, R.P., Stallings, M.C., Rhee, S.H., Crowley, T.J., & Hewitt, J.K. (2002). Substance use, abuse and dependence in adolescence: prevalence, symptom profiles and correlates. Drug & Alcohol Dependence, 68, 309-322.
101. Zacny, J.P., & Chait, L.D. (1991). Response to marijuana as a function of potency and breathhold duration. Psychopharmacology, 103, 223-226.
102. Zangen, A., Solinas, M., Ikemoto, S., Goldberg, S.R., & Wise, R.A. (2006). Two brain sites for cannabinoid reward. Journal of Neuroscience, 26, 4901-4907. (Pubitemid 44315331)
103. Zarrindast, M.R., Nouri, M., & Ahmendi, S. (2007). Cannabinoid CB1 receptors of the dorsal hippocampus are important for induction of conditioned place preference (CPP) but do not change morphine CPP. Brain Research, 1163, 130-137. (Pubitemid 47125867)